Search

Michael P Gamcsik

from Chapel Hill, NC
Age ~68

Michael Gamcsik Phones & Addresses

  • 206 Chesapeake Way, Chapel Hill, NC 27516 (919) 929-8361
  • 1214 Bivins St, Durham, NC 27707
  • Baltimore, MD
  • Kenner, LA
  • 206 Chesapeake Way, Chapel Hill, NC 27516 (919) 306-5639

Publications

Us Patents

Method Of Activation Of Oxazaphosphorines

View page
US Patent:
8399434, Mar 19, 2013
Filed:
Nov 6, 2007
Appl. No.:
12/375482
Inventors:
Ivan Spasojevic - Durham NC, US
Michael O. Colvin - Chapel Hill NC, US
Ines Batinic-Haberle - Durham NC, US
Susan M. Ludeman - Delmar NY, US
Michael P. Gamcsik - Chapel Hill NC, US
Assignee:
Duke University - Durham NC
International Classification:
A01N 57/00
A61K 31/675
US Classification:
514 90
Abstract:
The present invention provides a method of hydroxylating or oxidizing a compound of interest in a subject (e. g. , a cytotoxic oxazaphosphorine prodrug), by administering the compound of interest to the subject; and concurrently administering the subject a metalloporphyrin in an amount effective to hydroxylate or oxidize the compound of interest in the subject.

Method Of Treating Neuroblastoma

View page
US Patent:
20100104628, Apr 29, 2010
Filed:
Mar 28, 2008
Appl. No.:
12/531375
Inventors:
Susan M. Ludeman - Durham NC, US
Michael P. Gamcsik - Durham NC, US
Timothy A. Driscoll - Durham NC, US
James B. Springer - Durham NC, US
O. Michael Colvin - Durham NC, US
David J. Adams - Durham NC, US
Karel Base - Durham NC, US
Assignee:
Duke University - Durham NC
International Classification:
A61K 31/155
A61K 9/127
A61K 33/36
A61K 31/704
A61K 31/396
A61K 31/4375
A61K 31/216
A61P 35/00
US Classification:
424450, 424623, 514 34, 514183, 514283, 514549, 514634
Abstract:
The present invention relates, in general, to neuroblastoma and, in particular, to a method of treating neuroblastoma tumors, including refractory neuroblastoma tumors. The invention also relates to compounds and compositions suitable for use in such a method.

Method Of Activation Of Oxazaphosphorines

View page
US Patent:
20130172296, Jul 4, 2013
Filed:
Feb 8, 2013
Appl. No.:
13/763085
Inventors:
Duke University - Durham NC, US
Michael O. Colvin - Chapel Hill NC, US
Ines Batinic-Haberle - Durham NC, US
Susan M. Ludeman - Delmar NY, US
Michael P. Gamcsik - Chapel Hill NC, US
International Classification:
A61K 31/675
A61K 31/555
US Classification:
514110
Abstract:
The present invention provides a method of hydroxylating or oxidizing a compound of interest in a subject (e.g., a cytotoxic oxazaphosphorine prodrug), by administering the compound of interest to the subject; and concurrently administering the subject a metalloporphyrin in an amount effective to hydroxylate or oxidize the compound of interest in the subject.

Camptothecin Compounds With A Thioether Group

View page
US Patent:
6825206, Nov 30, 2004
Filed:
Nov 16, 2000
Appl. No.:
09/712912
Inventors:
Michael P. Gamcsik - Chapel Hill NC
David J. Adams - Chapel Hill NC
O. Michael Colvin - Chapel Hill NC
Monroe E. Wall - Chapel Hill NC
Mansukh C. Wani - Durham NC
Govindarajan Manikumar - Raleigh NC
Yves Pommier - Bethesda MD
Assignee:
Research Triangle Institute - Research Triangle Park NC
Duke University - Durham NC
National Institutes of Health - Rockville MD
International Classification:
A61K 3144
US Classification:
514283, 514 2, 514279
Abstract:
Camptothecin compounds which are effective anti-tumor compounds are disclosed. These conjugates inhibit the enzyme topoisomerase I and enhance the stability of the topoisomerase I-DNA cleavable complex.

Method Of Activation Of Oxazaphosphorines

View page
US Patent:
20140243294, Aug 28, 2014
Filed:
May 8, 2014
Appl. No.:
14/272779
Inventors:
- Durham NC, US
Michael O. Colvin - Chapel Hill NC, US
Ines Batinic-Haberle - Durham NC, US
Susan M. Ludeman - Delmar NY, US
Michael P. Gamcsik - Chapel Hill NC, US
Assignee:
DUKE UNIVERSITY - Durham NC
International Classification:
A61K 31/555
A61K 31/675
US Classification:
514110
Abstract:
The present invention provides a method of hydroxylating or oxidizing a compound of interest in a subject (e.g., a cytotoxic oxazaphosphorine prodrug), by administering the compound of interest to the subject; and concurrently administering the subject a metalloporphyrin in an amount effective to hydroxylate or oxidize the compound of interest in the subject.
Michael P Gamcsik from Chapel Hill, NC, age ~68 Get Report